Investment
Features
FeesSafety
Academy
More
Pluang+

NEOS Gold High Income ETF yields nearly 12% but faces NAV pressure amid gold price drops.

Market News
21 Jul 2026
Seeking Alpha
View Source
Neutral
pluang ai news

The NEOS Gold High Income ETF (IAUI) offers an attractive near 12% yield by using a synthetic covered call strategy on gold ETPs combined with U.S. treasuries for income. However, recent declines in gold prices have caused IAUI's net asset value (NAV) to drop about 8% year-to-date and distributions to fall 16% since January. While IAUI could outperform if gold prices remain stable, its capped upside and risk of further NAV erosion mean potential negative returns if gold prices decline more. Despite short-term challenges, the long-term outlook for IAUI remains positive for income-focused investors seeking diversification away from equities.

More News

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...

Company Fundamentals
Bullish
1 hour ago
Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...

Company Fundamentals
Bullish
1 hour ago
Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...

Analyst Insights
Bullish
2 hours ago
SAIC raises price target after beating Q2 earnings and boosting 2027 outlook

SAIC raises price target after beating Q2 earnings and boosting 2027 outlook

Science Applications International Corporation (SAIC) saw its price target raised to $154 after reporting Q2 earnings of $3.01 per share, surpassing estimates by over 33%, and revenues of $1.88 billion, beating expectations by 7.52%. The company also...

Analyst Insights
Bullish
3 hours ago
Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

UBS upgraded Hercules Capital's rating from Neutral to Buy, reflecting confidence in the company's strong financial stability and growth prospects. Hercules Capital, a specialty finance firm supporting tech and life sciences startups, boasts a BBB+ c...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App